The Biden administration is moving to reclassify marijuana as a Schedule III controlled substance, which will allow for easier research on its medical benefits. However, the change won't eliminate all restrictions or risks associated with the drug.
Key Points
Biden administration is proposing to reclassify marijuana as a Schedule III controlled substance
Current Schedule I classification imposes restrictions on studying marijuana
Reclassification may lead to more research on medical benefits and risks of cannabis
Pros
Easier for researchers to study marijuana
May lead to more research on the benefits of cannabis for medical conditions
Cons
Restrictions and risks associated with marijuana will not be entirely eliminated
Limited number of sources for researchers to obtain cannabis